Loading clinical trials...

Assessment of Vertigo and Dizziness in Individuals Following COVID-19 | Clinical Trials | Clareo Health

COMPLETED

Assessment of Vertigo and Dizziness in Individuals Following COVID-19

NCT06871280•Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Summary

This cross-sectional study aimed to assess the prevalence of dizziness/vertigo in individuals following COVID-19 and to investigate potential risk factors associated with these symptoms. A total of 296 patients aged 20-66 years who had recovered from COVID-19 were evaluated at Istanbul Physical Medicine and Rehabilitation Training and Research Hospital between June 1, 2021, and December 31, 2021. Clinical and demographic data, including COVID-19 history, comorbidities, and symptom characteristics, were collected. Dizziness-related disability was assessed using the Dizziness Handicap Inventory (DHI), while balance performance was evaluated with the Berg Balance Scale (BBS).

Eligibility

Age

20 - 66 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals aged 20-66 years.
•History of confirmed COVID-19 infection.
•Ability to speak and understand Turkish.
•Willingness to provide verbal and written informed consent.

Exclusion Criteria

•Pre-existing vertigo or balance disorders (e.g., benign paroxysmal positional vertigo, Ménière's disease, vestibular migraine, vestibular neuritis).
•Inner ear diseases or vestibular dysfunction.
•Neurological disorders affecting balance (e.g., multiple sclerosis, Parkinson's disease, history of stroke, epilepsy).
•Psychiatric conditions that could cause dizziness (e.g., anxiety, panic attacks, depression).
•History of head or neck trauma in the past six months.
•Moderate to severe visual impairment.
•Chronic alcohol or substance use.
•Use of ototoxic medications.
•Severe cardiovascular diseases (e.g., orthostatic hypotension, advanced heart failure, severe arrhythmias).
•Pregnant or breastfeeding women.
+2 more criteria

Locations (1)

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Istanbul, Turkey (Türkiye)

Key Dates

Start Date

June 1, 2021

Primary Completion Date

December 31, 2021

Completion Date

December 31, 2021

Last Updated

March 11, 2025

Enrollment

296

ACTUAL participants

Conditions

COVID-19

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

RECRUITINGPHASE1

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Assessment of Vertigo and Dizziness in Individuals Following COVID-19

Inclusion Criteria

Exclusion Criteria

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate

Positron Emission Tomography (PET) Imaging of Thrombosis